Fundamental Analysis of MERUS NV(NASDAQ:MRUS) stock

Fundamental Rating

We assign a fundamental rating of 3 out of 10 to MRUS. MRUS was compared to 587 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for MRUS as it has an excellent financial health rating, but there are worries on the profitability. MRUS is valied quite expensively at the moment, while it does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year MRUS has reported negative net income.

MRUS had a negative operating cash flow in the past year.

MRUS had negative earnings in each of the past 5 years.

In the past 5 years MRUS always reported negative operating cash flow.

1.2 Ratios

MRUS has a Return On Assets of -34.01%. This is in the better half of the industry: MRUS outperforms 67.35% of its industry peers.

Looking at the Return On Equity, with a value of -43.48%, MRUS is in the better half of the industry, outperforming 72.48% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-34.01%
ROE	-43.48%
ROIC	N/A

ROA(3y)-27.83%

ROA(5y)-28.28%

ROE(3y)-39.23%

ROE(5y)-48.66%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for MRUS so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

MRUS does not have a ROIC to compare to the WACC, probably because it is not profitable.

MRUS has more shares outstanding than it did 1 year ago.

Compared to 5 years ago, MRUS has more shares outstanding

There is no outstanding debt for MRUS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

An Altman-Z score of 13.49 indicates that MRUS is not in any danger for bankruptcy at the moment.

MRUS has a Altman-Z score of 13.49. This is amongst the best in the industry. MRUS outperforms 89.40% of its industry peers.

MRUS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	13.49

ROIC/WACCN/A

WACC7.28%

2.3 Liquidity

A Current Ratio of 5.34 indicates that MRUS has no problem at all paying its short term obligations.

MRUS has a Current ratio of 5.34. This is comparable to the rest of the industry: MRUS outperforms 56.58% of its industry peers.

A Quick Ratio of 5.34 indicates that MRUS has no problem at all paying its short term obligations.

MRUS's Quick ratio of 5.34 is in line compared to the rest of the industry. MRUS outperforms 57.27% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	5.34
Quick Ratio	5.34

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for MRUS have decreased by -3.10% in the last year.

MRUS shows a small growth in Revenue. In the last year, the Revenue has grown by 5.67%.

Measured over the past years, MRUS shows a small growth in Revenue. The Revenue has been growing by 2.75% on average per year.

EPS 1Y (TTM)-3.1%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q42.54%

Revenue 1Y (TTM)5.67%

Revenue growth 3Y13.65%

Revenue growth 5Y2.75%

Revenue growth Q2Q-16.22%

3.2 Future

Based on estimates for the next years, MRUS will show a very strong growth in Earnings Per Share. The EPS will grow by 21.16% on average per year.

The Revenue is expected to grow by 57.87% on average over the next years. This is a very strong growth

EPS Next Y-10.32%

EPS Next 2Y-5.87%

EPS Next 3Y1.01%

EPS Next 5Y21.16%

Revenue Next Year-12.24%

Revenue Next 2Y17.43%

Revenue Next 3Y37.05%

Revenue Next 5Y57.87%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

MRUS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MRUS. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-5.87%

EPS Next 3Y1.01%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

MRUS does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

MERUS NV

NASDAQ:MRUS (5/16/2024, 2:12:03 PM)

45.27

+0.06 (+0.13%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap2.66B

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-34.01%
ROE	-43.48%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.1

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	5.34
Quick Ratio	5.34
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)-3.1%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y-10.32%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)5.67%

Revenue growth 3Y13.65%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

MERUS NV (MRUS)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens